A Meta-Analysis of Randomized Controlled Trial on Efficacy of Naltrexone/Bupropion for Anthropological Parameter, Lipid profile, Blood Glucose and Blood Pressure
Article Sidebar
Main Article Content
Abstract
Previous studies reported that Naltrexone/Bupropion (NB) improved several metabolic parameters but there were no a meta-analysis in these outcomes. Objectives : This study aimed to assess NB efficacy for improving anthropological parameters, lipid profile, blood glucose and blood pressure. Material and methods : The databases included PubMed, Scopus, CINAHL from inception to August 2017. For this analysis, we selected randomized placebo versus NB intervention trials. We performed a quality assessment of the retrieved studied using Jadad’s scoring and Cochrane’s risk of bias assessment. Results : Six studies (11,733 participants) met inclusion criteria. Meta-analysis revealed a reduction in body weight (weight mean difference; WMD -5.02 kg; 95%CI : -6.49, -3.54), waist circumference (WMD -3.70 cm; 95% CI -4.60, -2.80). Similar results were observed for LDL-cholesterol (WMD -3.34 mg/dL; 95% CI -5.67, -1.02), TG (WMD -11.90 mg/dL; 95% CI -14.78, -9.02) and increased HDL significantly (WMD 3.82 mg/dL; 95% CI 2.88, 4.77). Moreover, participants administrated NB significant reduction in fasting insulin (WMD -0.91 mIU/mL; 95% CI -1.25, -0.57) and HOMA-IR (WMD -0.68; 95% CI -0.54, -0.21). No serious adverse effects were found in either the NB or comparator groups. Conclusion : NB improved anthropological parameters, lipid profile, fasting insulin and HOMA-IR.
Article Details
In the case that some parts are used by others The author must Confirm that obtaining permission to use some of the original authors. And must attach evidence That the permission has been included
References
Apovian CM, Aronne L, Rubino D, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring) 2013;21(5):935-43
Billes SK, Sinnayah P, Cowley MA. Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. Pharmacol Res 2014;84:1-11.
Braz NF, Carneiro MV, Oliveira-Ferreira F, et al. Influence of aerobic training on cardiovascular and metabolic parameters in elderly hypertensive women. Int J Prev Med 2012; 3(9): 652–9.
Caixàs A, Albert L, Capel I, Rigla M. Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date. Drug Des Devel Ther 2014; 8: 1419–27.
Chen Y, Copeland WK, Vedanthan R, et al. Association between body mass index and cardiovascular disease mortality in East Asians and south Asians: pooled analysis of prospective data from the Asia Cohort Consortium. BMJ 2013; DOI: 10.1136/bmj.f5446.
Christou GA., Kiortsis DN. The efficacy and safety of the naltrexone/bupropion combination for the treatment of obesity: an update. Hormones 2015, 14(3):370-75.
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7(3):177-88.
Després JP. Body fat distribution and risk of cardiovascular disease: an update. Circulation. 2012;126(10):1301-13.
Filippatos TD, Rizos EC, Gazi IF, et al. Differences in metabolic parameters and cardiovascular risk between American Diabetes Association and World Health Organization definition of impaired fasting glucose in European Caucasian subjects: a cross-sectional study. Arch Med Sci 2013; 9(5): 788–95.
Gaziano TA, Bitton A, Anand S, et al. Growing epidemic of coronary heart disease in low- and middle-income countries. Curr Probl Cardiol 2010; 35(2):72-115.
Greenway FL, Dunayevich E, Tollefson G, et al. Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. J Clin Endocrinol Metab 2009;94(12):4898-906.
Greig SL, Keating GM. Naltrexone/bupropion ER: a review in obesity management. Drugs 2015;75(11):1269-80.
Gu Q, Burt VL, Paulose-Ram R, et al. High blood pressure and cardiovascular disease mortality risk among U.S. adults: the third National Health and Nutrition Examination Survey mortality follow-up study. Ann Epidemiol 2008; 18:302-9.
Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928 doi: 10.1136/bmj.d5928
Higgins JPT, Thomson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327(7414):557-60.
Hollander P, Gupta AK, Plodkowski R, et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care 2013;36(12):4022-9.
Izzo AA, Hoon-Kim S, Radhakrishnan R, et al. A critical approach to evaluating clinical efficacy, adverse events and drug interactions of herbal remedies. Phytother Res 2016;30(5):691-700.
Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996;17(1):1-2.
Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151(4):264-9
Nissen SE, Wolski KE, Prcela L, et al. Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial. JAMA 2016;315(10):990-1004.
Port SC, Boyle NG, Hsueh WA, et al. The Predictive Role of Blood Glucose for Mortality in Subjects with Cardiovascular Disease. Am J Epidemiol 2006; 163(4):342–51.
Ross R, Janiszewski PM. Is weight loss the optimal target for obesity-related cardiovascular disease risk reduction?. Can J Cardiol 2008; 24(Suppl):25-31.
Sahebkar A. Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis. Phytother Res 2014; 28(5):633-642.
Sherman MM, Ungureanu S, Rey JA. Naltrexone/bupropion ER (Contrave): newly approved treatment option for chronic weight management in obese adults. Drug Forecast 2016;41(3):164-72.
Smith SR, Fujioka K, Gupta AK, et al. Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity. Diabetes Obes Metab 2013;15(9):863-6.
Thase ME, Haight BR, Johnson MC, et al. A randomized, double-blind, placebo-controlled study of the effect of sustained-release bupropion on blood pressure in individuals with mild untreated hypertension. J Clin Psychopharmacol 2008;28(3):302-307.
Verpeut JL, Bello NT. Drug safety evaluation of naltrexone/bupropion for the treatment of obesity. Expert Opin Drug Saf 2014;13(6):831-41.
Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring) 2011;19(1):110-20.
WHO. Cardiovascular diseases (CVDs), Fact Sheet, 2009 [Online]. 2016 December 25 [cited 2016 Dec 25]. Available from : http://www.who.int/mediacentre/factsheets/fs317/en/.